Novavax Reports FY2025 Profitability, Secures Pfizer Adjuvant Deal, and New $330M Credit Facility
NVAX sits 89% above its 52-week low of $5.01.
Summary
Novavax reported a significant return to profitability in FY2025, driven by APA terminations and new licensing revenue. The company also announced a major Matrix-M adjuvant deal with Pfizer and secured a new $330 million credit facility, bolstering its financial position despite ongoing liquidity management.
Key Events · Earnings and Guidance · NVAX
-
Return to Profitability in FY2025
Novavax reported a net income of $440.3 million for the fiscal year ended December 31, 2025, a substantial improvement from a net loss of $187.5 million in 2024. This was significantly boosted by the recognition of $575.7 million from the termination of the Canada APA and $27.3 million from the New Zealand APA as product sales.
-
New Pfizer Licensing Agreement for Matrix-M Adjuvant
In January 2026, Novavax entered a non-exclusive license agreement with Pfizer for its Matrix-M adjuvant technology in up to two infectious disease areas. The agreement includes a $30 million upfront payment, potential for up to $500 million in development and sales milestones, and tiered high mid-single digit royalties on sales.
-
Secured New $330 Million Senior Secured Term Loan Facility
In February 2026, Novavax entered a Credit Agreement with MidCap Financial Trust for a senior secured term loan facility of up to $330 million. The first tranche of $50 million was funded at closing, providing immediate liquidity. The facility is secured by a first-priority lien on substantially all company assets.
-
Significant Milestones Achieved from Sanofi Collaboration
Novavax earned $225 million in milestones in FY2025 under the Sanofi Collaboration and License Agreement, including $175 million for US FDA BLA approval of Nuvaxovid and $50 million for the transfer of EU and US marketing authorizations. An additional $425 million in potential milestones remain.
Analysis · NVAX · Life Sciences
Novavax's 2025 annual report signals a significant turnaround, moving from a net loss of $187.5 million in 2024 to a net income of $440.3 million in 2025. This return to profitability is largely driven by the termination of advance purchase agreements (APAs) with Canada and New Zealand, which allowed for the recognition of $575.7 million and $27.3 million, respectively, in product sales from previously deferred revenue. The company also secured a new, substantial non-exclusive licensing agreement with Pfizer in January 2026 for its Matrix-M adjuvant technology, including a $30 million upfront payment and potential for up to $500 million in development and sales milestones, plus tiered royalties. This deal validates Novavax's core technology and provides a significant new revenue stream. Furthermore, Novavax strengthened its liquidity with a new senior secured term loan facility of up to $330 million from MidCap Financial Trust, with $50 million funded at closing in February 2026. While the company still faces challenges, including a decrease in overall cash and cash equivalents, ongoing discussions regarding the Australian APA, and a history of losses, these strategic partnerships and the return to profitability represent a material positive shift in its financial trajectory and future prospects.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NVAX was trading at $9.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $5.01 to $10.64. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.